Medicago announced on Thursday that it will be shutting down its COVID-19 vaccine project in Quebec. As a result, 586 jobs in the province will be affected. The closure comes as Medicago’s sole shareholder, the Japan-based Mitsubishi Chemical Group, decided to stop marketing the Covifenz vaccine.
- After Medicago shutdown, Canada recovers $40M and research on COVID-19 vaccine
- New COVID-19 drug can cut hospitalizations by half in high-risk patients, study finds
- Medicago to cease operations in Quebec, scuttling COVID-19 vaccine production plans